Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

Robocath successfully completes first robotic coronary angioplasties in Belgium

May 04, 2021

News Industry News

Zebra Technologies Introduces Smart, Non-Invasive Way for Hospitals to Track, Provide Real-Time Feedback on Patients with Acute Myocardial Infarction

August 26, 2015

News Industry News

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

May 21, 2014

News Industry News

Tryton Medical Announces Events at EuroPCR 2014 in Paris

May 12, 2014

News Industry News

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013

News Industry News

FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings

May 14, 2012

News Industry News

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

August 15, 2011

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Industry News

St. Jude Medical to Showcase PCI Optimization Technology and Structural Heart Portfolio at EuroPCR

May 16, 2011

Advertisement

Robocath successfully completes first robotic coronary angioplasties in Belgium

Zebra Technologies Introduces Smart, Non-Invasive Way for Hospitals to Track, Provide Real-Time Feedback on Patients with Acute Myocardial Infarction

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Tryton Medical Announces Events at EuroPCR 2014 in Paris

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

St. Jude Medical to Showcase PCI Optimization Technology and Structural Heart Portfolio at EuroPCR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content